Press Releases Soleno Therapeutics, Inc.

Equities

SLNO

US8342033094

Real-time Estimate Cboe BZX Other stock markets 02:10:12 2024-04-30 pm EDT			5-day change	1st Jan Change
45.66 ^USD	+0.30%		+14.71%	+14.40%

Apr. 29	Soleno Therapeutics' Shares Jump After FDA Grants Breakthrough Designation for Prader-Willi Syndrome Treatment	MT
Apr. 29	Soleno Therapeutics Gets Breakthrough Therapy Designation for Diazoxide Choline	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Soleno Therapeutics Announces Peer-Reviewed Publication of Data Comparing DCCR Treatment to the Natural History of Prader-Willi Syndrome	08:02am	AQ
Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)	Apr. 29	AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - April 19, 2024	Apr. 22	AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 19	AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 08	AQ
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results	Mar. 06	AQ
Soleno Therapeutics : March 2024 Corporate Presentation	Mar. 04	PU
Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference	Feb. 22	AQ
Soleno Therapeutics to Present at Upcoming February Investor Conferences	Feb. 01	AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Jan. 29	AQ
Soleno Therapeutics Strengthens Leadership Team with Key Appointments	Jan. 24	AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Jan. 05	AQ
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Nov. 10	AQ
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results	Nov. 07	AQ
Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open-Label Study of DCCR in Prader-Willi Syndrome	Nov. 06	AQ
PWS children who switch from DCCR see worsening hyperphagia: Trial	23-10-06	PU
Correcting & Replacing -- Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium	23-10-04	AQ
Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research Symposium	23-10-04	AQ
Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares	23-10-02	AQ
Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants	23-09-28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Soleno Therapeutics, Inc.

Equities

SLNO

US8342033094

Press Releases

Filters